Foresight News reported that Anixa Biosciences (NASDAQ: ANIX), a publicly traded company in the United States, announced that its board has approved the purchase of Bitcoin as a treasury reserve asset, aiming to diversify the company's assets while allowing Anixa to benefit from the potential long-term value of digital assets.
Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention.
